HEALTH TECHNOLOGY

Northwell Health and Aegis Ventures Launch Ascertain – Healthcare AI Company Creation Platform to Improve Quality and Access to Care

Northwell Health | April 13, 2022

Northwell Health

Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a New York-based startup studio announced at their inaugural Healthcare AI Innovation Summit the finalization of definitive agreements to launch Ascertain, a joint company creation platform. Ascertain is a first-of-its-kind partnership that pairs a dynamic venture studio with one of the nation’s largest and most impactful health systems to develop and commercialize breakthrough healthcare AI companies that improve quality and access to care and close health equity gaps.

Ascertain represents a novel, more targeted approach to the way entrepreneurs and healthcare systems collaborate to solve major healthcare challenges. The platform combines clinical and business leadership, expert technical and product teams, access to Northwell’s leading, diverse datasets, and capital resources within a single ecosystem – with a sole focus on building and validating effective solutions that can be rapidly brought to market.

Ascertain brings a unique structure, an innovative approach, and a compelling vision to create breakthrough healthcare AI companies that are set up for success. We are all driven by the idea that everyone deserves access to high-quality, affordable healthcare. Our aim is clear: to find new, cost-efficient ways to create and accelerate companies that deliver real, equitable solutions.”

Michael Dowling, President and CEO of Northwell Health

Ascertain has commenced the creation of its first portfolio companies in partnership with Northwell’s clinicians and administrators. One such collaboration is focused on bringing substantive improvements in maternal health, working hand-in-hand with Northwell’s recently launched Center for Maternal Health to develop new approaches to detecting and managing serious complications for expectant mothers and babies. Ascertain’s data science team has been working hand-in-hand with Northwell’s Maternal and Fetal Medicine team to examine tens of thousands of cases of preeclampsia, a hypertensive pregnancy complication that disproportionately affects Black mothers in the United States.

Using cutting-edge data science techniques, the Ascertain team aims to deliver an AI solution that helps clinicians predict the risk of developing preeclampsia, enabling them to intervene earlier than previously possible.

“Existing approaches to the detection of preeclampsia often occur too late in pregnancy, once the condition has begun to manifest. An important enabler for a solution to this challenge is predictive analytics, applying available knowledge of a patient's history to enable action far earlier with simple, yet life-saving, clinical interventions. We believe the AI solution Ascertain is currently developing will enable this,” shared Burt Rochelson, MD, Chief of Maternal Medicine at Northwell Health.

“Aegis and Northwell’s multidisciplinary teams are pursuing innovation through a systematic approach that will bring validated solutions to patients more quickly and at a lower cost,” said Bill Schoenfeld, Aegis Ventures Chairman. “Our skillsets are extraordinarily complementary and enable us to address healthcare’s most entrenched quality, equity, and cost problems far more powerfully than either organization could alone.”

Ascertain is preparing to launch multiple companies in 2022 that focus on maternal health, chronic disease detection and management, and next-generation AI tools.

Ascertain’s Chairman Tom Manning shared, “Together, we’re paving a new way forward, a monumental step toward real, proven AI solutions that can bring impact to the world. It is a bold collaboration to drive AI-backed companies that save lives and resolve long-standing health inequities – and realize results that deliver something greater in healthcare.”

Ascertain is committed to building exceptional teams that will embrace this unique opportunity to create unparalleled impact. To learn more about Ascertain or register your interest, please visit https://ascertain.com/.

About Ascertain
Ascertain is a revolutionary new partnership between Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a dynamic startup studio. This unique partnership assembles leading medical, technology, and business resources to create a first-of-its-kind company creation platform for healthcare innovation to address healthcare’s most challenging quality, equity, and cost problems. Ascertain brings $100M in seed-stage capital to bear in pursuit of a three-pronged approach to company creation: internal ideation, commercialization of scientific breakthroughs, and US market entry partnerships for global ventures. Ascertain creates companies that improve quality of care, patient experience, and long-standing health, placing patient needs at the center of every business model, technology solution, and product.

About Northwell Health
Northwell Health is New York State’s largest healthcare provider and private employer, with 23 hospitals, 830 outpatient facilities and more than 16,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 77,000 employees – 18,900 nurses and 4,800 employed doctors, including members of Northwell Health Physician Partners – are working to change healthcare for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies.

About Aegis Ventures
Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies. Our platform brings together market-shaping ideas, permanent growth capital, and ambitious individuals driven to solve major societal problems. We aim to build companies with the capacity for vast impact, with an initial focus on artificial intelligence and digital health. Within these verticals, Aegis seeks to create companies that leverage technology to better optimize tradeoffs between quality, access, and cost, focusing on innovations that promote seamless continuity of care, patient empowerment, and better-informed clinical decision-making.

Spotlight

The brain is the most important organ in the body. But incredibly, there's no standard routine assessment for brain health. Looking after the brain should be our top priority.

Spotlight

The brain is the most important organ in the body. But incredibly, there's no standard routine assessment for brain health. Looking after the brain should be our top priority.

Related News

HEALTH TECHNOLOGY

GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity

GE Healthcare | November 18, 2022

GE Healthcare’s Pharmaceutical Diagnostics business announced an $80 million investment to increase manufacturing capacity by 30 percent at its Active Pharmaceutical Ingredients site in Lindesnes, Norway. The investmentwhich is creating around 100 new jobs – is part of GE Healthcare’s broader commitment to address significant future global demand for iodinated contrast media, used in Xray and Computed Tomography procedures around the world to enhance visualization of organs, blood vessels and tissues across disease pathways. Iohexol and iodixanol API are used in over 100 million patient doses of GE iodinated contrast media annually, equivalent to three patient procedures every second. This new investment, coupled with the recent opening of a new production line at GE Healthcare’s Cork, Ireland, fill and finish facility, aims to enable the production of 30 million more patient doses per year by 2025. “We expect global demand for iodinated contrast media to double in the next 10 years, driven by global prevalence of chronic disorders and significant growth in CT procedures. This investment in capacity expansion at our Lindesnes facility is another example of how we, as an industry leader, are addressing this growing demand to meet the needs of our customers and their patients across the globe.” President & CEO of GE Healthcare Pharmaceutical Diagnostics, Kevin O’Neill The 100-acre Lindesnes site in southern Norway, has been operating since 1974 and employs 450 people, who use multiple chemical pharmaceutical processes to convert iodine into finished API. Recently, GE Healthcare announced a multi-year agreement with SQM, a Chile-based mining company, to secure increasing supply of iodine, the key ingredient in iodinated contrast media. GE Healthcare is the world’s leading supplier of contrast media, used to support patient imaging procedures in 130+ countries globally. All stages of its contrast media manufacturing, from development of Active Pharmaceutical Ingredient (API) to finished product, are managed entirely by GE Healthcare, adhering to current Good Manufacturing Practices. With over 4000 employees globally and seven manufacturing sites, the Pharmaceutical Diagnostics business also develops and supplies radiopharmaceuticals used to support diagnosis, monitoring and treatment selection across Neurology, Cardiology and Oncology clinical pathways. About GE Healthcare GE Healthcare is the $17.7 billion healthcare business of GE. As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Read More

HEALTH TECHNOLOGY

HCA Healthcare Strengthens Partnership with Tennessee State University

HCA Healthcare, Inc. | October 07, 2022

HCA Healthcare, Inc. one of the nation’s leading healthcare providers, announced that it will give $1.5 million to Tennessee State University to create scholarship opportunities for students enrolled in the Dr. Levi Watkins, Jr. Institute and the Department of Computer Science within the College of Engineering. This gift is part of the organization’s larger commitment to give $10 million over three years to Historically Black Colleges and Universities (HBCUs) and Hispanic Serving Institutions. Since making the pledge in 2021, HCA Healthcare has announced approximately $5.25 million in donations towards multiple partnerships. “We are proud of the long-standing relationship we have fostered with TSU. By strengthening our partnership, we will be able to create additional opportunities for TSU students and further our commitment to advancing diversity in healthcare.” Sam Hazen, chief executive officer for HCA Healthcare Funds from this gift will support scholarships for students participating in the university’s Dr. Levi Watkins, Jr. Institute Accelerated Medical Pathway program. Three two-year scholarships for rising juniors and three two-year scholarships for graduate students within the College of Engineering will also be awarded. Through these scholarship programs, HCA Healthcare Scholars and HCA Healthcare ITG Scholars will be provided with hands on shadowing opportunities, mentors, seminars, leadership sessions, guest speakers and career guidance. HCA Healthcare will also offer dedicated internship opportunities in the ITG Pathways, Technical Resident and Part-Time Internship programs annually to TSU students. “It is an honor to partner with TSU to support more students pursuing careers in healthcare and, in turn, helping to build a diverse talent pipeline of healthcare professionals,” said Sherri Neal, chief diversity officer of HCA Healthcare. “Increasing the diversity of our healthcare workforce is vital to providing equitable, culturally competent care to our communities.” HCA Healthcare has a history of partnering with TSU. In 2015, HCA Healthcare gave $1 million to TSU to fund internship opportunities and support the growth of the Health Information Management program. Marty Paslick, chief information officer for HCA Healthcare, serves as an advisory board member for the College of Engineering where there are currently seven HCA Healthcare colleagues serving as adjunct faculty. “We applaud and thank HCA Healthcare for this generous gift and continued support of TSU, and our talented students,” said Glenda Glover, president of Tennessee State University. “This investment in our students helps them to become the future doctors and health technology leaders they aspire to be. HCA Healthcare is making their dreams a reality.” HCA Healthcare is committed to partnering with organizations to help develop a diverse pool of future healthcare leaders. Included among these partnerships is $750,000 to The University of Texas at El Paso to create multiple graduate-degree opportunities for students interested in healthcare careers. The company also gifted $1.5 million to Florida International University’s (FIU) Nicole Wertheim College of Nursing & Health Sciences (NWCNHS) to expand its faculty, offer scholarships to increase enrollment and help address the national nursing shortage. In 2021, HCA Healthcare announced a $1.5 million investment in Florida A&M University’s (FAMU) School of Allied Health Sciences to strengthen students’ pathways from undergraduate to graduate to management careers in the healthcare industry. In 2019, the HCA Healthcare Scholars at Fisk University program was created to provide scholarships, career planning support and internship opportunities for high-achieving undergraduates. These partnerships and others with industry- and school-based associations are part of HCA Healthcare’s continued efforts to strengthen the diversity of the organization’s talent pipeline. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 182 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its more than 35 million annual patient encounters to advance science, improve patient care and save lives. About Tennessee State University Founded in 1912, Tennessee State University is Nashville’s only public university, and is a premier, historically black university and land-grant institution offering 39 bachelor’s degree programs, 25 master’s degree programs, one education specialist degree, and eight doctoral degrees. TSU is a comprehensive research intensive institution with a R-2 Carnegie designation, and has a graduate school on its downtown Avon Williams Campus, along with the Otis Floyd Nursery Research Center in McMinnville, Tennessee. With a commitment to excellence, Tennessee State University provides students with a quality education in a nurturing and innovative environment that prepares them as alumni to be global leaders in every facet of society.

Read More

HEALTH TECHNOLOGY

Trukera™ Medical Launches New ScoutPro™ Osmolarity System

Trukera Medical | September 13, 2022

Trukera™ Medical last week announced a corporate rebranding to reflect thea company’s expanded vision and strategic growth plans targeting broader unmet needs in corneal health. Trukera Medical unveiled the first product under the new company name, the ScoutPro™ Osmolarity System. Designed to help advance corneal health decisions for today’s busy eye care practices, ScoutPro is the first and only portable osmometer in the U.S. “The ScoutPro Osmolarity System is an exciting technology developed around the evolving needs of today’s eye care professionals. Premium cataract and refractive practices are now the fastest growing adopters of osmolarity testing, given the prevalence of hyperosmolarity in their patient demographics and the risk it poses to compromising corneal cell health and driving refractive instability. More than ever, these practices require patient care solutions that can seamlessly adapt into established operational models, not the other way around, to deliver a premium patient experience, efficiency of care, and minimize staff time and disruptions. We’re proud to bring a solution to market addressing these needs, and to help more practices objectively identify and manage such a critical component to patient’s corneal health and refractive outcomes.” Adam Szaronos, Trukera Medical CEO The ScoutPro Osmolarity System brings together nanoliter volume sample collection and analysis in a single portable device. Users can now bring laboratory testing to patients anywhere in the practice to quickly test and provide objective results in the palm of their hand. The system is built upon the company’s established accuracy trusted in over 24 million tests globally to date, with an industry-leading precision. “Toxic hyperosmolarity damages sensitive corneal nerves and may cause refractive instability. As cornea and cataract/refractive specialists, we are cognizant of the importance of this to our surgical outcomes and the overall health of our patients’ eyes. ScoutPro gives us the ability to precisely determine osmolarity quickly and easily, without disrupting patient flow,” said Dr. Lisa Nijm, Chief Medical Advisor for Ophthalmology at Trukera Medical and Corneal Surgeon at Warrenville Eye Care and LASIK Center in Illinois. The ScoutPro Osmolarity System is now available for pre-order in the U.S. and will be commercially launched at the upcoming World Cornea Congress and the American Academy of Ophthalmology later this month. About Trukera Medical Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera Medical’s expanding portfolio includes ScoutPro, the first and only portable osmolarity system in the U.S. The company’s dedicated focus is improving corneal health, both as a primary goal and in preparation for surgery.

Read More